PhaseBio Pharmaceuticals, Inc.

103 articles with PhaseBio Pharmaceuticals, Inc.

• PhaseBio Enters Worldwide License Agreement With MedImmune for a Reversal Agent for Ticagrelor

  11/28/2017

  Ticagrelor is unique among P2Y12 antagonist antiplatelet agents due to its ability to reversibly bind to the receptor, whereas other P2Y12 antagonists bind permanently.

• PhaseBio Announces Leadership Team Appointments

  4/7/2016

• PhaseBio Receives FDA Orphan Drug Designation For Vasomera (PB1046) For The Treatment Of Cardiomyopathy Associated With Dystrophinopathies

  12/1/2015

• PhaseBio Announces Initiation Of Phase IIa Multiple Ascending Dose Study Of Once-Weekly Basal Insulin PE0139 In Type 2 Diabetes

  11/9/2015

• PhaseBio To Present At Rodman & Renshaw 17th Annual Global Investment Conference

  9/3/2015

• PhaseBio Announces Positive Data For Type 2 Diabetes Treatments PE0139 And PB1023

  6/8/2015

• PhaseBio To Present At The American Diabetes Association 75th Scientific Sessions

  6/2/2015

• PhaseBio Announces Promising Pre-Clinical Results For PB1046 In Models Of Duchenne Muscular Dystrophy

  4/22/2015

• AstraZeneca PLC-Backed PhaseBio Locks in $40 Million

  3/12/2015

• PhaseBio Pharmaceuticals, Inc. Announces Expansion Of Leadership Team

  3/3/2015

• PhaseBio Pharmaceuticals, Inc. Expands Clinical Development of Vasomera, an Investigational Treatment for Cardiopulmonary Diseases

  6/18/2013

• PhaseBio Pharmaceuticals, Inc. Initiated Phase 1 Study of Investigational Once-Weekly Basal Insulin for Potential Treatment of Diabetes

  6/4/2013

• PhaseBio Pharmaceuticals, Inc. to Present at the Jefferies and Co. 2013 Global Healthcare Conference

  5/29/2013

• PhaseBio Pharmaceuticals, Inc. Positions for the Next Stage of Development by Bringing on Board Industry Veteran, Jonathan Mow as Chief Business Officer

  12/4/2012

• PhaseBio Pharmaceuticals, Inc. Initiates a Multicenter, Randomized Placebo and Active Comparator Controlled Phase 2b Trial to Evaluate Use of Glymera for the Treatment of Uncontrolled Type 2 Diabetes

  8/21/2012

• PhaseBio Pharmaceuticals, Inc. Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing for Advancement of Metabolic and Cardiovascular Product Portfolio

  6/5/2012

• PhaseBio Pharmaceuticals, Inc. Launches Clinical Program to Evaluate Novel VPAC2 Agonist for Cardiovascular Disease

  2/22/2012

• PhaseBio Pharmaceuticals, Inc. Announces Positive Clinical Results with its Once Weekly GLP-1 analogue, Glymera™ for the Treatment of Hyperglycemia in Patients with Type 2 Diabetes

  11/15/2011

• PhaseBio Pharmaceuticals, Inc. Announces the Appointment of Kathryn J. Gregory Vice President of Business Development

  4/27/2011

• PhaseBio Pharmaceuticals, Inc. Reaches Key Milestones and Receives $15 Million to Complete Series B Financing

  12/2/2010